Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14

Benzinga Newsdesk www.benzinga.com Positive 89.7%

Neg 0% Neu 0% Pos 89.7%

Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $13.5 to $14.